Company development strategy

Within the framework of the strategy for the development of the pharmaceutical industry of the Russian Federation, which is aimed at reducing the dependence of domestic health care on the import of medicines, Binergia JSC has identified the following areas of its activities as priorities:

  • Production of high-tech generics and innovative bioorganic drugs.
  • Development and production of active pharmaceutical ingredients.
  • Research, development and production of innovative pharma drugs.
  • Market launch of modern and affordable medicines.
  • Ensuring control and maintaining a high level of quality at all stages, from an idea to production.

In addition, the company is focused on the production of drugs that are significant to society. More than 60% of the range of products are drugs that are included in the List of Vital and Essential Medicines (VEM). These are critical drugs for both patients and the health care system as a whole.

Being in dynamic development, we strive to provide the population of Russia with safe, high-quality, effective and, least but not last, affordable medicines.